Market News
7 min read | Updated on August 08, 2025, 08:01 IST
SUMMARY
Hindustan Petroleum Corporation (HPCL) reported an over six-fold jump in its consolidated net profit for the first quarter of the current fiscal year (Q1 FY26) to ₹4,110.93 crore from ₹633.94 crore posted in the year-ago period
Godrej Consumer Products Limited posted a marginal increase in its consolidated net profit for Q1 FY26 to ₹452.5 crore. | Image: Shutterstock
The RBI's approval came after AU Small Finance Bank fulfilled the RBI's minimum paid-up capital/net worth requirement as applicable to become a universal bank. The bank showcased a satisfactory track record of performance as an SFB for a minimum period of five years and also fulfilled RBI’s due diligence exercise.
The company's net premium income jumped 4.71% year-on-year (YoY) to ₹1.2 lakh crore during the reporting quarter, rising from ₹1.14 lakh crore in Q1 FY25.
LIC's non-par APE (annualised premium equivalent) share within the individual business was at 30.34% during the reporting quarter against 23.94% in the year-ago quarter.
Titan's revenue from operations advanced 25% annually to ₹16,523 crore in the April-June period from ₹13,266 crore in the year-ago period.
The company reported strong operational performance as its earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 47% annually to ₹1,830 crore and its operating profit margin expanded by 170 basis points to 11.08%.
The profit jumped as much as 548.4% year-on-year (YoY) on the back of inventory gains and a margin surge because of holding retail fuel prices despite a drop in input oil cost. The Q1 FY26 profit is more than half of the full FY25 earnings, which were at ₹6,735.70 crore.
However, the company's turnover remained stable during Q1 FY26 at ₹1.20 lakh crore as against ₹1.21 lakh crore in the June quarter of FY25.
The company’s revenue from operations during the reporting quarter jumped 10% year-on-year (YoY) to ₹3,662 crore as compared to ₹3,331.6 crore in Q1 FY25.
The FMCG major reported earnings before interest, taxes, depreciation, and amortisation (EBITDA) of ₹694.8 crore during the June quarter, down 4% from ₹724.4 crore in the same quarter of the previous fiscal year. Margin stood at 19% in Q1 FY26 against 21.7% in Q1 FY25.
Its revenue from operations rose 35% year-on-year (YoY) to ₹6,171.17 crore in the quarter under review, compared to ₹4,586.60 crore in the first quarter of FY25.
At an operational level, its EBITDA increased 39% YoY to ₹525 crore in Q1FY26, as against ₹379 crore in the June FY25 quarter. Its EBITDA margin expanded by 20 basis points (bps) to 8.5% during the reporting quarter, compared to 8.3% in Q1FY25.
The company's revenue from operations stood at ₹7,268 crore, growing 31% YoY in Q1 FY25, compared to ₹5,528 crore in Q1 FY25. The robust revenue growth across markets and categories was aided by strong same-store-sales growth (SSSG).
On the operational level, Kalyan Jewellers’ EBITDA came in at ₹508 crore in contrast to ₹368 crore in the same quarter of the previous fiscal year, marking a jump of 38%. The EBITDA margin was also flat at 7% in Q1 FY26 as against 6.6% YoY.
The exchange posted record quarterly revenues of ₹1,044 crore in the April-June quarter of FY26, a sharp 56% increase from ₹668 crore in the first quarter ended June 30, 2024. During the quarter, BSE's equity derivatives segment recorded a total of 498 crore contracts traded, generating ₹598 crore in revenue.
Consolidated revenue in the first quarter stood at ₹1,998 crore as against ₹2,138 crore in the year-ago period, down 7%.
Commenting on the performance, Crompton Greaves Consumer Electricals MD & CEO Promeet Ghosh said, "We navigated a challenging quarter due to unseasonal weather, impacting cooling products, offset by strong growth in solar pumps and small domestic appliances."
Total revenue declined to ₹4,022 crore in the June quarter as against ₹4,567 crore in the year-ago period, Biocon Ltd said in a statement.
"Biocon opened FY26 with a strong performance, driven by continued gains in biosimilars and CRDMO and a steady showing in generics," Kiran Mazumdar-Shaw, Chairperson, Biocon Group, stated.
About The Author
Next Story